Valentin Feichtenschlager, MD
Associate Specialist
Dermatology
School of Medicine

Publications (12)

Top publication keywords:
Interleukin-2TOR Serine-Threonine KinasesSkin NeoplasmsMelanomaGTP PhosphohydrolasesMAP Kinase Signaling SystemProto-Oncogene Proteins B-rafOligonucleotides, AntisenseMembrane ProteinsMitogen-Activated Protein Kinase KinasesCell Line, TumorRNA, Long NoncodingLymphatic MetastasisApoptosisMice

• LB1005 Suppression of NRAS-mutant melanoma growth with NRAS-targeting ASO treatment reveals therapeutically relevant kinase co-dependencies.
  Journal of Investigative Dermatology 2024 V. FEICHTENSCHLAGER, Y.J. Zheng, T. Qu, D. Hohlova, C. Callanan, L. Chen, C. Chen, W. Ho, A. Lee, Y. Hwang, D.P. Muñoz, K. Rappersberger, J. Coppe, S. Ortiz-Urda
• The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
  Molecular cancer 2024 Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, …
• The therapeutically actionable long non-coding RNA 'T-RECS' is essential to cancer cells' survival in NRAS/MAPK-driven melanoma.
  Research square 2023 Feichtenschlager V, Chen L, Zheng YJ, Ho W, Sanlorenzo M, Vujic I, Fewings E, Lee A, Chen C, Callanan C, Lin K, Qu T, Hohlova D, Vujic M, Hwang Y, Lai K, Chen S, Nguyen T, Muñoz DP, Kohwi Y, Posch C, …
• Deconstructing the role of MALAT1 in MAPK-signaling in melanoma: insights from antisense oligonucleotide treatment.
  Oncotarget 2023 Feichtenschlager V, Zheng YJ, Ho W, Chen L, Callanan C, Chen C, Lee A, Ortiz J, Rappersberger K, Ortiz-Urda S
• 672 Targeting lncRNAs AC and BX reveals their critical role in melanoma and allows to identify novel phosphor-catalytic vulnerabilities.
  Journal of Investigative Dermatology 2020 V. Feichtenschlager, C. Emily, M. Vujic, I. Vujic, C. Chen, A. Lee, S. Ortiz-Urda

Show all (7 more) Hide

• Clinical melanoma characteristics and survival-a single-center retrospective study between 2000 and 2010.
  Wiener medizinische Wochenschrift (1946) 2019 Feichtenschlager V, Weihsengruber F, Richter L, Vujic I, Rappersberger K, Posch C
• 184 Discovering the hidden elements of cancer: Targeting the lncrna ac004540.4 reveals its critical role in nras mutant melanoma.
  Journal of Investigative Dermatology 2018 V. Feichtenschlager, L. Chen, M. Vujic, A. Lee, H. Kao, J. Zheng, S. Ortiz
• 185 The antisense lncRNA transcript RP11-7O11.3: Shedding light upon a novel and crucial player in NRAS mutant melanoma.
  Journal of Investigative Dermatology 2018 L. Chen, V. Feichtenschlager, M. Vujic, A. Lee, H. Kao, J. Zheng, S. Ortiz
• 497 Eleven years of melanoma patient management – observations and trends from a single-center study in Austria.
  Journal of Investigative Dermatology 2016 C. Posch, V. Feichtenschlager, F. Weihsengruber, K. Rappersberger
• Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.
  Oncotarget 2014 Vujic I, Posch C, Sanlorenzo M, Yen AJ, Tsumura A, Kwong A, Feichtenschlager V, Lai K, Arneson DV, Rappersberger K, Ortiz-Urda SM
• Low-dose inhalation of interleukin-2 bio-chemotherapy for the treatment of pulmonary metastases in melanoma patients.
  British journal of cancer 2014 Posch C, Weihsengruber F, Bartsch K, Feichtenschlager V, Sanlorenzo M, Vujic I, Monshi B, Ortiz-Urda S, Rappersberger K
• Combined targeting of MEK and PI3K/mTOR effector pathways is necessary to effectively inhibit NRAS mutant melanoma in vitro and in vivo.
  Proceedings of the National Academy of Sciences of the United States of America 2013 Posch C, Moslehi H, Feeney L, Green GA, Ebaee A, Feichtenschlager V, Chong K, Peng L, Dimon MT, Phillips T, Daud AI, McCalmont TH, LeBoit PE, Ortiz-Urda S